Share this article

ConcertAI has introduced its next-generation CTO 2.0 solution for supporting design and execution of clinical trials.

The new solution, released for clinical trial optimisation, now has three new features.

It has expanded data assets through sources that are publicly available for including site and physician level trial information on existing and previous trials.

In partnership with data partners, working operational trial metrics and site profile information it helps highlight trial performance and capabilities of study centres.

The solution also includes social determinants of health information at the physical site as well as the physician/patient levels.

Using the latest information, CTO 2.0 will be able to provide recommendations that automate the selection process of trial sites through a data-driven approach.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Additionally, the SaaS technology will help clinicians and researchers select suitable sites for clinical trials.

This balances potential participants available and previous trial performances at the trial sites to provide the highest likelihood of a study success.

Trial operators will also be able to comply with the FDA mandate that trials should provide meaningful information for the subject outcomes.

CTO 2.0 also ensures research can be conducted at scale using the latest clinical informatics integrations and data standards.

ConcertAI COO Ronan Brown said: “There is a practical and moral imperative to make clinical trials available to all patients, which naturally means expansion of trials into community settings, where over 75% of patients receive their care.

“This aligns with the FDA mandate, and also with the urgent necessity to increase trial diversity. CTO 2.0 is a direct response to these needs.”